EP3917507A4 - Tumescent infiltration drug delivery of cannabinoids - Google Patents

Tumescent infiltration drug delivery of cannabinoids Download PDF

Info

Publication number
EP3917507A4
EP3917507A4 EP20747957.7A EP20747957A EP3917507A4 EP 3917507 A4 EP3917507 A4 EP 3917507A4 EP 20747957 A EP20747957 A EP 20747957A EP 3917507 A4 EP3917507 A4 EP 3917507A4
Authority
EP
European Patent Office
Prior art keywords
cannabinoids
drug delivery
tumescent infiltration
infiltration drug
tumescent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20747957.7A
Other languages
German (de)
French (fr)
Other versions
EP3917507A1 (en
Inventor
Jeffrey Alan Klein
Paytra Alan Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HK Pharma
Original Assignee
HK Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/264,440 external-priority patent/US11241412B2/en
Application filed by HK Pharma filed Critical HK Pharma
Publication of EP3917507A1 publication Critical patent/EP3917507A1/en
Publication of EP3917507A4 publication Critical patent/EP3917507A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP20747957.7A 2019-01-31 2020-01-30 Tumescent infiltration drug delivery of cannabinoids Pending EP3917507A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/264,440 US11241412B2 (en) 2015-10-12 2019-01-31 Tumescent infiltration drug delivery of cannabinoids
PCT/US2020/015963 WO2020160328A1 (en) 2019-01-31 2020-01-30 Tumescent infiltration drug delivery of cannabinoids

Publications (2)

Publication Number Publication Date
EP3917507A1 EP3917507A1 (en) 2021-12-08
EP3917507A4 true EP3917507A4 (en) 2022-11-09

Family

ID=71840463

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20747957.7A Pending EP3917507A4 (en) 2019-01-31 2020-01-30 Tumescent infiltration drug delivery of cannabinoids

Country Status (2)

Country Link
EP (1) EP3917507A4 (en)
WO (1) WO2020160328A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10493024B2 (en) 2015-10-12 2019-12-03 Hk Tumescent Pharma Corporation Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011066577A1 (en) * 2009-11-30 2011-06-03 Jeffrey Alan Klein Tumescent antibiotic solution
US20130116223A1 (en) * 2009-03-02 2013-05-09 Doris Hexsel Medicinal cosmetic lipoatrophy
WO2018081740A1 (en) * 2016-10-28 2018-05-03 The Regents Of The University Of California Tumescent antibiotic injection for treatment of chronic skin and soft tissue infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2240022B1 (en) * 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
US8808734B2 (en) * 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
US10493024B2 (en) * 2015-10-12 2019-12-03 Hk Tumescent Pharma Corporation Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116223A1 (en) * 2009-03-02 2013-05-09 Doris Hexsel Medicinal cosmetic lipoatrophy
WO2011066577A1 (en) * 2009-11-30 2011-06-03 Jeffrey Alan Klein Tumescent antibiotic solution
WO2018081740A1 (en) * 2016-10-28 2018-05-03 The Regents Of The University Of California Tumescent antibiotic injection for treatment of chronic skin and soft tissue infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GREGG J M ET AL: "Cardiovascular effects of cannabinol during oral surgery", ANESTHESIA AND ANALGESIA 1976, vol. 55, no. 2, 1976, pages 203 - 213, XP009539446, ISSN: 0003-2999 *
See also references of WO2020160328A1 *

Also Published As

Publication number Publication date
EP3917507A1 (en) 2021-12-08
WO2020160328A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
AU2018295533A1 (en) Device for subcutaneous delivery of fluid medicament
EP3538078A4 (en) Formulations for efficient delivery of cannabinoids
EP3518981A4 (en) Delivery of therapeutic rnas via arrdc1-mediated microvesicles
EP4045024A4 (en) Transdermal delivery of cannabidiol
EP3383456A4 (en) Systems and methods for controlled drug delivery pumps
EP3813853A4 (en) Compositions for drug delivery and methods of use thereof
EP3941561A4 (en) Nasal drug delivery system
EP3941630A4 (en) Precise delivery of components into fluids
EP3731846A4 (en) Drug delivery systems for treatment of infections
EP3413909A4 (en) Subcutaneous delivery of adenovirus with dual targeting
EP3934717A4 (en) Delivery of fluid from a syringe
EP3664885A4 (en) Transdermal drug delivery system
EP4007564A4 (en) Intracranial delivery of medicinal solution
EP3777893A4 (en) Use of bis-iminobiotin compound for drug delivery purposes
EP3888726A4 (en) Liquid delivery pump
EP3917507A4 (en) Tumescent infiltration drug delivery of cannabinoids
EP3720422A4 (en) Liposomal system for drug delivery
EP3661576A4 (en) Medical nebulizer for fast drug delivery
EP4081206A4 (en) Preparation of cannabichromene and related cannabinoids
EP3250261A4 (en) Fluid pump assembly and loading of same into a fluid delivery system
EP4049698A4 (en) Drug delivery device
EP4006057A4 (en) Complex for intracellular delivery of molecules
EP3982929A4 (en) Hydrogel drug delivery composition
EP3958972A4 (en) Therapeutic drug for dyskinesia
EP3836866A4 (en) Systems for enteric delivery of therapeutic agents

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210826

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066815

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20221010

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 23/02 20060101ALI20221004BHEP

Ipc: A61K 31/522 20060101ALI20221004BHEP

Ipc: A61K 31/352 20060101ALI20221004BHEP

Ipc: A61K 31/137 20060101AFI20221004BHEP